AlloVir, Inc. (ALVR)
Largest Insider Buys in Sector
ALVR Stock Price History Chart
ALVR Stock Performance
About AlloVir, Inc.
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, …
Insider Activity of AlloVir, Inc.
Over the last 12 months, insiders at AlloVir, Inc. have bought $0 and sold $214,047 worth of AlloVir, Inc. stock.
On average, over the past 5 years, insiders at AlloVir, Inc. have bought $36.7M and sold $13.14M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,930,870 shares for transaction amount of $10.99M was made by GILEAD SCIENCES, INC. (10 percent owner) on 2023‑06‑27.
List of Insider Buy and Sell Transactions, AlloVir, Inc.
| 2024-11-19 | Sale | See Remarks | 3,186 0.0026% | $0.55 | $1,748 | +4.69% | ||
| 2024-11-19 | Sale | Chief Executive Officer | 8,706 0.0072% | $0.55 | $4,775 | +4.69% | ||
| 2024-11-19 | Sale | General Counsel | 432 0.0004% | $0.55 | $237 | +4.69% | ||
| 2024-11-19 | Sale | Chief Accounting Officer | 554 0.0005% | $0.55 | $304 | +4.69% | ||
| 2024-11-05 | Sale | See Remarks | 5,136 0.0044% | $0.86 | $4,442 | +14.48% | ||
| 2024-11-05 | Sale | Chief Executive Officer | 10,609 0.0091% | $0.86 | $9,176 | +14.48% | ||
| 2024-11-05 | Sale | General Counsel | 2,272 0.002% | $0.86 | $1,965 | +14.48% | ||
| 2024-11-05 | Sale | Chief Accounting Officer | 1,655 0.0014% | $0.86 | $1,431 | +14.48% | ||
| 2024-10-22 | Sale | See Remarks | 1,882 0.0016% | $0.77 | $1,445 | 0.00% | ||
| 2024-10-22 | Sale | General Counsel | 766 0.0007% | $0.77 | $588 | 0.00% | ||
| 2024-10-22 | Sale | Chief Accounting Officer | 486 0.0004% | $0.77 | $373 | 0.00% | ||
| 2024-10-21 | Sale | See Remarks | 1,546 0.0013% | $0.78 | $1,204 | -29.72% | ||
| 2024-10-21 | Sale | Chief Executive Officer | 9,752 0.0085% | $0.78 | $7,597 | -29.72% | ||
| 2024-10-21 | Sale | General Counsel | 635 0.0006% | $0.78 | $495 | -29.72% | ||
| 2024-10-21 | Sale | Chief Accounting Officer | 479 0.0004% | $0.78 | $373 | -29.72% | ||
| 2024-10-03 | Sale | See Remarks | 940 0.0008% | $0.81 | $766 | -30.34% | ||
| 2024-10-03 | Sale | Chief Executive Officer | 1,493 0.0013% | $0.81 | $1,217 | -30.34% | ||
| 2024-10-03 | Sale | General Counsel | 377 0.0003% | $0.81 | $307 | -30.34% | ||
| 2024-10-03 | Sale | Chief Accounting Officer | 301 0.0003% | $0.81 | $245 | -30.34% | ||
| 2024-08-20 | Sale | Chief Executive Officer | 5,390 0.0046% | $0.74 | $3,996 | +0.72% |
Insider Historical Profitability
| Brainard Diana | Chief Executive Officer | 723363 0.6259% | $0.40 | 1 | 34 | +5.55% |
| GILEAD SCIENCES, INC. | 10 percent owner | 16635286 14.3945% | $0.40 | 1 | 0 | <0.0001% |
| Jovan-Embiricos Morana | director | 342693 0.2965% | $0.40 | 1 | 7 | +5.55% |
| VAN BEEK JEROEN B | Chief Commercial Officer | 333726 0.2888% | $0.40 | 1 | 34 | +5.55% |
| Atillasoy Ercem | See Remarks | 131372 0.1137% | $0.40 | 1 | 8 | +5.55% |
Institutional Investor Ownership
| Ecor1 Capital Llc | $8.53M | 9.82 | 11.29M | New | +$8.53M | 0.06 | |
| Artal Group S A | $4.98M | 5.74 | 6.6M | 0% | +$0 | 0.02 | |
| Octagon Capital Advisors LP | $3.17M | 3.65 | 4.2M | New | +$3.17M | 0.02 | |
| BlackRock | $2.56M | 2.94 | 3.39M | -3.98% | -$105,898.13 | <0.0001 | |
| Millennium Management LLC | $2.22M | 2.56 | 2.94M | -24.63% | -$725,761.69 | <0.01 |